The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

Pharmaceuticals are exempt from the cascade of 'Liberation Day' tariffs revealed by President Donald Trump – for now – but ...

TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...

The agreement with the GKV-Spitzenverband – the national association of statutory health insurance funds – means that Hemgenix (etranacogene dezaparvovec) can now be reimbursed across Germany's health ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...

Traditional DCTs primarily focus on prospective data collection, adapting interventional research processes to virtual approaches and providing an incomplete picture of patients. This approach offers ...

Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency ...

Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, according to a new study, which also suggests ...

The latest rejection looks set to mark the end of J&J's drive to resolve the litigation through the bankruptcy courts, as the ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

At Reuters Pharma USA in Philadelphia, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US ...